Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICMAD Beefs Up Lobbying To Deter 'Wrong Decision' In Congress

Executive Summary

Pam Busiek, head of the Independent Cosmetic Manufacturers and Distributors, discusses the trade group's ongoing work in Washington where multiple, differently sized bills for updating cosmetics regulations are under consideration. Notably, ICMAD's roster of advocates now includes former FDA Cosmetics Director John Bailey.

Advertisement

Related Content

ICMAD Focuses On Education With Membership Up 26% In Five Years
Rep. Pallone Has Cosmetics Concerns, Possibly Coming To A Storefront Near You
Rep. Pallone's Push For Cosmetics Reform Falls Flat During OTC Monograph Bill Markup
Cosmetics News In Brief: Sen. Hatch Retirement; SMEs Receive EU REACH Support
Surprise Hatch Bill Lays Middle Ground For Cosmetic Regulatory Reform
Cosmetics Reform Bill Relaunches In Senate, Sending Stakeholders To Familiar Corners
ICMAD Clutches To House Cosmetics Bill Before Specter Of ‘Activist FDA’

Topics

Advertisement
UsernamePublicRestriction

Register

RS121459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel